Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis

Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis

Background: Anti-tumor necrosis factor-α (TNF-α) agents are effective for moderately to severely active ulcerative colitis (UC). Nonetheless, a proportion of patients fail to respond to these agents as therapy for induction of remission. Recent studies indicated that perinuclear anti-neutrophil cyto...

Full description

Bibliographic Details
Main Authors: Atsushi Yoshida, Katsuyoshi Matsuoka, Fumiaki Ueno, Toshio Morizane, Yutaka Endo, Toshifumi Hibi
Format: Article
Language:English
Published: Karger Publishers 2021-04-01
Series:Inflammatory Intestinal Diseases
Subjects:
inflammatory bowel disease
primary failure
infliximab
adalimumab
golimumab
Online Access:https://www.karger.com/Article/FullText/515361

Similar Items

Similar Items